 TransCode Therapeutics Inc NASDAQ: RNAZ is trading higher after preclinical research supporting its lead candidate, TTX-MC138, was published in Cancer Nanotechnology. Related: TransCode Therapeutics Secures NIH Funding To Support Its Lead Program Development. 